Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,956 questions in 143 reviews · Musculoskeletal
current versionsNo studies 555 · 28.4%Ungraded 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Febuxostat 80 mg/day vs allopurinol Discontinuations due to adverse events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.3 [0.79, 2.1] | 3 studies · 1044 participants | Moderate |
Febuxostat 120 mg/day vs allopurinol Incidence of gout flares · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.3 [0.87, 1.9] | 2 studies · 986 participants | High |
Febuxostat 120 mg/day vs allopurinol Serum uric acid <6.0 mg/dL at final visit · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 2.2 [1.9, 2.5] | 2 studies · 880 participants | Moderate |
Febuxostat 120 mg/day vs allopurinol Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs allopurinol Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs placebo Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs allopurinol Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs allopurinol Serious Adverse Events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.2 [0.7, 1.93] | 3 studies · 1041 participants | High |
Febuxostat 120 mg/day vs allopurinol Discontinuations due to adverse events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.6 [0.49, 5] | 3 studies · 1041 participants | High |
Febuxostat 40 mg/day vs placebo Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs placebo Serious Adverse Events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1 [0, 0] | 1 study · 75 participants | Moderate |
Febuxostat 40 mg/day vs placebo Discontinuations due to adverse events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1 [0.07, 15.8] | 1 study · 75 participants | Moderate |
Febuxostat 80 mg/day vs placebo Incidence of gout flares · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.32 [0.96, 1.8] | 2 studies · 474 participants | Low |
Febuxostat 80 mg/day vs placebo Serum uric acid <6.0 mg/dL at final visit · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 68.9 [13.8, 343.9] | 2 studies · 332 participants | Low |
Nefopam 60 mg tds vs placebo Pain VAS 100mm · patients with pain management in rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis (2012) · Cochrane | no estimate extracted | 2 studies · 48 participants | Low |
Nefopam 60 mg tds vs placebo Withdrawal Due to adverse events · patients with pain management in rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis (2012) · Cochrane | RR 11 [0.64, 189.65] | 1 study · 54 participants | Moderate |
Nefopam 60 mg tds vs placebo Total adverse events · patients with pain management in rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis (2012) · Cochrane | RR 4.11 [1.58, 10.69] | 2 studies · 104 participants | Low |
Capsaicin 0.025% vs placebo Pain (% reduction from baseline) VAS 100mm · patients with Knee pain in patients with rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis (2012) · Cochrane | no estimate extracted | 1 study · 30 participants | Low |
Capsaicin 0.025% vs placebo Pain (% reduction from baseline) VAS 100mm · patients with Knee pain in patients with rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis (2012) · Cochrane | no estimate extracted | 1 study · 29 participants | Low |
Oromucosal cannabis (Sativex) vs placebo Pain at present McGill short form questionnaire ‐ Verbal rating scale (0‐5) · patients with pain management in patients with rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis (2012) · Cochrane | no estimate extracted | 1 study · 58 participants | Low |
Oromucosal cannabis (Sativex) vs placebo Quality of Sleep Numerical rating scale (0‐10). Scale from: 0 to 10. · patients with pain management in patients with rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis (2012) · Cochrane | no estimate extracted | 1 study · 58 participants | Low |
Oromucosal cannabis (Sativex) vs placebo Withdrawal due to adverse events · patients with pain management in patients with rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis (2012) · Cochrane | RR 0.13 [0.01, 2.39] | 1 study · 58 participants | Low |
Oromucosal cannabis (Sativex) vs placebo Total adverse events · patients with pain management in patients with rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis (2012) · Cochrane | RR 1.82 [1.1, 3] | 1 study · 58 participants | Low |
Muscle relaxant vs control Pain ‐ 24hrs (Single dose) · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | no estimate extracted | 3 studies · 104 participants | Low |
Muscle relaxant vs control Pain ‐ 1‐2 weeks · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | no estimate extracted | 3 studies · 104 participants | Very low |
Muscle relaxant vs control Withdrawal due to Adverse Events · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | RR 2.84 [0.31, 26.08] | 5 studies · 180 participants | Very low |
Muscle relaxant vs control Total Number of Adverse Events ‐ only studies >24hrs duration · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | RR 4.03 [1.08, 15.1] | 2 studies · 74 participants | Very low |
Muscle relaxant vs control Total Number of Adverse Events ‐ single dose studies · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | RR 1.4 [0.58, 3.41] | 3 studies · 106 participants | Very low |
Muscle relaxant vs control CNS adverse events · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | RR 5.96 [1.77, 20.08] | 2 studies · 74 participants | Very low |
MAOIs vs placebo Pain (VAS) VAS from: 0 to 10 · patients with fibromyalgia syndrome Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome (2012) · Cochrane | no estimate extracted | 2 studies · 121 participants | Low |
MAOIs vs placebo Tender points Tender point score and number of tender points · patients with fibromyalgia syndrome Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome (2012) · Cochrane | no estimate extracted | 2 studies · 121 participants | Low |
MAOIs vs placebo Global assessment (by patient) VAS from: 0 to 10 · patients with fibromyalgia syndrome Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome (2012) · Cochrane | no estimate extracted | 2 studies · 121 participants | Low |
MAOIs vs placebo Physical function · patients with fibromyalgia syndrome Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome (2012) · Cochrane | no estimate extracted | NR | No studies |
MAOIs vs placebo Discontinuation due to adverse events · patients with fibromyalgia syndrome Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome (2012) · Cochrane | no estimate extracted | 2 studies · 149 participants | Low |
MAOIs vs placebo Adverse events (nausea and vomiting) · patients with fibromyalgia syndrome Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome (2012) · Cochrane | no estimate extracted | 1 study · 89 participants | Low |
MAOIs vs placebo Sleep disturbance · patients with fibromyalgia syndrome Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Total number of fractures radiographs · preventing and treating osteoporosis in postmenopausal women Exercise for preventing and treating osteoporosis in postmenopausal women (2011) · Cochrane | OR 0.61 [0.23, 1.64] | 4 studies · 539 participants | High |
Intervention NR Bone mineral density % change: spine · preventing and treating osteoporosis in postmenopausal women Exercise for preventing and treating osteoporosis in postmenopausal women (2011) · Cochrane | no estimate extracted | 24 studies · 1441 participants | High |
Intervention NR Bone mineral density % change: femoral neck · preventing and treating osteoporosis in postmenopausal women Exercise for preventing and treating osteoporosis in postmenopausal women (2011) · Cochrane | no estimate extracted | 19 studies · 1338 participants | Low |
Intervention NR Bone mineral density % change: total hip · preventing and treating osteoporosis in postmenopausal women Exercise for preventing and treating osteoporosis in postmenopausal women (2011) · Cochrane | no estimate extracted | 13 studies · 863 participants | High |
Intervention NR Bone mineral density % change: trochanter · preventing and treating osteoporosis in postmenopausal women Exercise for preventing and treating osteoporosis in postmenopausal women (2011) · Cochrane | no estimate extracted | 10 studies · 815 participants | High |
Intervention NR Adverse events: Falls · preventing and treating osteoporosis in postmenopausal women Exercise for preventing and treating osteoporosis in postmenopausal women (2011) · Cochrane | no estimate extracted | 3 studies · 378 participants | Ungraded |
Intervention NR Other adverse events · preventing and treating osteoporosis in postmenopausal women Exercise for preventing and treating osteoporosis in postmenopausal women (2011) · Cochrane | no estimate extracted | 11 studies · 907 participants | Ungraded |
Intervention NR ACR 50% improvement ‐ not measured · patients with treating rheumatoid arthritis Herbal therapy for treating rheumatoid arthritis (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Participants (n) reported adverse events ( · patients with Rheumatoid arthritis Herbal therapy for treating rheumatoid arthritis (2011) · Cochrane | RR 1.36 [0.49, 3.82] | 1 study · 23 participants | Low |
Intervention NR Change in radiographic progression ‐ not measured · patients with Rheumatoid arthritis Herbal therapy for treating rheumatoid arthritis (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Achievement of low disease state (DAS 28) ‐ not measured · patients with Rheumatoid arthritis Herbal therapy for treating rheumatoid arthritis (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain Visual Analogue Scale. Scale from: 0 to 100. ( · patients with treating rheumatoid arthritis Herbal therapy for treating rheumatoid arthritis (2011) · Cochrane | no estimate extracted | 3 studies · 82 participants | Moderate |
Intervention NR Disability (HAQ score) percent change. Scale from: 0 to 100. ( · patients with treating rheumatoid arthritis Herbal therapy for treating rheumatoid arthritis (2011) · Cochrane | no estimate extracted | 1 study · 41 participants | Low |
Intervention NR Participants (n) reported adverse events ( · patients with treating rheumatoid arthritis Herbal therapy for treating rheumatoid arthritis (2011) · Cochrane | RR 4.24 [0.78, 22.99] | 2 studies · 61 participants | Moderate |